

# Emmanuel Stip

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8550142/publications.pdf>

Version: 2024-02-01

123  
papers

2,815  
citations

186265

28  
h-index

233421

45  
g-index

143  
all docs

143  
docs citations

143  
times ranked

4056  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 25-34.	2.4	2
2	More than just anti-NMDAR: the many facets of autoimmune encephalitis. <i>BJPsych Bulletin</i> , 2022, 46, 197-201.	1.1	2
3	Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study. <i>British Journal of Psychiatry</i> , 2022, 220, 347-354.	2.8	8
4	Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 469-480.	4.5	11
5	The Impact of the COVID-19 "Infodemic" on Well-Being: A Cross-Sectional Study. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 289-307.	2.7	15
6	Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 456-468.	4.5	4
7	Editorial: Novel Approaches to Improve Detection, Differentiation and Treatment in Mood Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 837283.	2.6	0
8	Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 216, 173376.	2.9	7
9	Neural alterations of emotion processing in atypical trajectories of psychotic-like experiences. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	2
10	COVID-19, Healthcare Workers and Mental Wellbeing: Lessons From One Very Cold and Another Very Hot Part of the World. <i>Canadian Journal of Psychiatry</i> , 2022, , 070674372210943.	1.9	0
11	Multidimensional analysis of adult patients'™ care trajectories before a first diagnosis of schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	7
12	Facing Confinement, the Comfort of WhatsApp Groups in Mental Health Communities. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 63-64.	1.9	5
13	When should psychiatrists think of anti-NMDA receptor encephalitis? A systematic approach in clinical reasoning. <i>Asian Journal of Psychiatry</i> , 2021, 56, 102524.	2.0	2
14	The Roko Syndrome: A Mirror of Koro Syndrome. <i>Journal of Psychosexual Health</i> , 2021, 3, 88-91.	0.6	1
15	Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. <i>Addiction</i> , 2021, 116, 2431-2442.	3.3	30
16	Disaster management of the psychological impact of the COVID-19 pandemic. <i>International Journal of Emergency Medicine</i> , 2021, 14, 19.	1.6	55
17	Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: Systematic review, meta-analysis and meta-regression analyses of double-blind randomised controlled trials. <i>Journal of Psychopharmacology</i> , 2021, 35, 910-918.	4.0	6
18	People with mental illness should be included in COVID-19 vaccination. <i>Lancet Psychiatry</i> , the, 2021, 8, 275-276.	7.4	8

#	ARTICLE	IF	CITATIONS
19	The psychological impact of the COVID-19 pandemic on adults and children in the United Arab Emirates: a nationwide cross-sectional study. <i>BMC Psychiatry</i> , 2021, 21, 224.	2.6	66
20	Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties. <i>Molecular Psychiatry</i> , 2021, 26, 7093-7097.	7.9	6
21	Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2021, 46, 2101-2111.	5.4	7
22	Classical Koro and Koro-Like Symptoms: Illustration from Canada. <i>Journal of Psychosexual Health</i> , 2021, 3, 222-235.	0.6	5
23	Urbanicity, Schizophrenia and Equitable Specialist Services Allocation. <i>Canadian Journal of Psychiatry</i> , 2021, , 070674372110406.	1.9	0
24	Pattern of psychiatric in-patient admissions in Al Ain, United Arab Emirates. <i>BJPsych International</i> , 2021, 18, 46-50.	1.4	5
25	Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. <i>Microbial Biotechnology</i> , 2020, 14, 69-79.	1.7	24
26	Measures of gluten-related reactivity in children with autism spectrum disorders in the absence of overt gastrointestinal symptoms: a pilot study from the United Arab Emirates. <i>Journal of International Medical Research</i> , 2020, 48, 030006052095265.	1.0	3
27	Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532095711.	2.7	1
28	Mutations associated with neuropsychiatric conditions delineate functional brain connectivity dimensions contributing to autism and schizophrenia. <i>Nature Communications</i> , 2020, 11, 5272.	12.8	35
29	Bibliotherapy: Reading OVID During COVID. <i>Frontiers in Psychiatry</i> , 2020, 11, 567539.	2.6	8
30	From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs). <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1325-1332.	2.8	3
31	Psychiatry and COVID-19: The Role of Chlorpromazine. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 739-740.	1.9	15
32	Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. <i>International Clinical Psychopharmacology</i> , 2020, 35, 221-228.	1.7	15
33	Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic. <i>Asian Journal of Psychiatry</i> , 2020, 54, 102203.	2.0	10
34	Chronic Neuroleptic-Induced Parkinsonism Examined With Positron Emission Tomography. <i>Movement Disorders</i> , 2020, 35, 1189-1198.	3.9	3
35	The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 577678.	3.5	29
36	Reward-related decision-making in schizophrenia: A multimodal neuroimaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 286, 45-52.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Incidentaloma Discoveries in the Course of Neuroimaging Research. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 275-279.	0.5	5
38	Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2019, 11, 139-147.	1.7	5
39	Effects of high intensity interval training among overweight individuals with psychotic disorders: A randomized controlled trial. <i>Schizophrenia Research</i> , 2019, 210, 278-286.	2.0	31
40	The screen for cognitive impairment in psychiatry (SCIP) is associated with disease severity and cognitive complaints in major depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 49-56.	2.4	13
41	Multisite generalizability of schizophrenia diagnosis classification based on functional brain connectivity. <i>Schizophrenia Research</i> , 2018, 192, 167-171.	2.0	43
42	Catatonia with schizophrenia: From ECT to rTMS. <i>L'Encephale</i> , 2018, 44, 183-187.	0.9	15
43	11.1 EFFECT OF INTERVAL TRAINING ON METABOLIC RISK FACTORS IN OVERWEIGHT INDIVIDUALS WITH PSYCHOSIS: A RANDOMIZED CONTROLLED TRIAL. <i>Schizophrenia Bulletin</i> , 2018, 44, S17-S17.	4.3	4
44	Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 287-301.	2.7	28
45	Sex, Age, Symptoms and Illness Duration and Their Relation with Gyrfication Index in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2018, 12, 57-68.	1.4	4
46	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. <i>Psychopharmacology Bulletin</i> , 2018, 48, 25-61.	0.0	9
47	Understanding access and use of technology among youth with first-episode psychosis to inform the development of technology-enabled therapeutic interventions. <i>Microbial Biotechnology</i> , 2017, 11, 72-76.	1.7	52
48	First clinical use of epidural stimulation in catatonia. <i>Brain Stimulation</i> , 2017, 10, 859-861.	1.6	7
49	A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment. <i>Psychopharmacology</i> , 2017, 234, 1045-1058.	3.1	5
50	Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 827-836.	1.9	13
51	Suicidal Ideation and Schizophrenia: Contribution of Appraisal, Stigmatization, and Cognition. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 726-734.	1.9	11
52	Impaired Coupling between the Dorsomedial Prefrontal Cortex and the Amygdala in Schizophrenia Smokers Viewing Anti-smoking Images. <i>Frontiers in Psychiatry</i> , 2017, 8, 109.	2.6	2
53	Altered brain connectivity in patients with schizophrenia is consistent across cognitive contexts. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 17-26.	2.4	17
54	Physician Characteristics Associated With Prescription of Long-Acting Injectable Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1060.	2.2	2

#	ARTICLE	IF	CITATIONS
55	Cost Reductions Associated With Long-Acting Injectable Antipsychotics According to Patient Age. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1061.	2.2	6
56	An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 9, 198-208.	1.4	18
57	Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. <i>Case Reports in Psychiatry</i> , 2016, 2016, 1-3.	0.5	1
58	Internet Addiction, Hikikomori Syndrome, and the Prodromal Phase of Psychosis. <i>Frontiers in Psychiatry</i> , 2016, 7, 6.	2.6	76
59	Antibiotic-associated encephalopathy Author Response. <i>Neurology</i> , 2016, 87, 1188-1189.	1.1	7
60	Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia. <i>Journal of Sports Sciences</i> , 2016, 34, 1500-1515.	2.0	15
61	Increased ventro-medial prefrontal activations in schizophrenia smokers during cigarette cravings. <i>Schizophrenia Research</i> , 2016, 173, 30-36.	2.0	20
62	Evidence from paranoid schizophrenia for more than one component of theory of mind. <i>Frontiers in Psychology</i> , 2015, 6, 1643.	2.1	8
63	Anandamide Is Involved in Appetite-Related Amygdala Hyperactivations in Schizophrenia Patients Treated With Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 82-83.	1.4	3
64	Impact of the resolution of brain parcels on connectome-wide association studies in fMRI. <i>NeuroImage</i> , 2015, 123, 212-228.	4.2	44
65	Emotion processing in treatment-resistant schizophrenia patients treated with clozapine: An fMRI study. <i>Schizophrenia Research</i> , 2015, 168, 377-380.	2.0	18
66	Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 147-154.	3.2	12
67	The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S1-4.	1.9	0
68	Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S26-34.	1.9	42
69	Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S40-7.	1.9	14
70	Who pioneered the use of antipsychotics in North America?. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S5-13.	1.9	27
71	Saliency network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S35-9.	1.9	11
72	Daily Task Performance and Information Processing among People with Schizophrenia and Healthy Controls: A Comparative Study. <i>British Journal of Occupational Therapy</i> , 2014, 77, 466-474.	0.9	9

#	ARTICLE	IF	CITATIONS
73	A microstructural study of sleep instability in drug-naive patients with schizophrenia and healthy controls: Sleep spindles, rapid eye movements, and muscle atonia. <i>Schizophrenia Research</i> , 2014, 155, 31-38.	2.0	16
74	Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. <i>Community Mental Health Journal</i> , 2013, 49, 317-322.	2.0	6
75	Redevelopment of tertiary psychiatric services in British Columbia: A prospective study of clinical, social, and residential outcomes of former long-stay inpatients. <i>Schizophrenia Research</i> , 2013, 149, 96-103.	2.0	6
76	Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 24-32.	1.8	14
77	Clozapine and visuospatial processing in treatment-resistant schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2013, 18, 615-630.	1.3	23
78	The Incidence and Nature of Cerebellar Findings in Schizophrenia: A Quantitative Review of fMRI Literature. <i>Schizophrenia Bulletin</i> , 2013, 39, 797-806.	4.3	71
79	The Neural Correlates of Mental Rotation Abilities in Cannabis-Abusing Patients with Schizophrenia: An fMRI Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-10.	1.5	11
80	A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia. <i>Frontiers in Pharmacology</i> , 2013, 4, 100.	3.5	26
81	Genealogy of instruments for prodrome evaluation of psychosis. <i>Frontiers in Psychiatry</i> , 2013, 4, 25.	2.6	25
82	About the nature of contextual impairments revealed by FN400 abnormalities in schizophrenia. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 60.	2.0	3
83	Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-12.	1.5	67
84	Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders. <i>Drug Safety</i> , 2012, 35, 819-836.	3.2	28
85	Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. <i>Psychiatry Research</i> , 2012, 200, 237-241.	3.3	40
86	Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile. <i>Pain Medicine</i> , 2012, 13, 1571-1579.	1.9	44
87	Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 713-732.	2.4	20
88	ERP investigation of study-test background mismatch during face recognition in schizophrenia. <i>Schizophrenia Research</i> , 2012, 134, 101-109.	2.0	26
89	A Study of Theory of Mind in Paranoid Schizophrenia: A Theory or Many Theories?. <i>Frontiers in Psychology</i> , 2012, 3, 432.	2.1	31
90	Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2012, 3, 85.	2.6	19

#	ARTICLE	IF	CITATIONS
91	Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders. <i>International Clinical Psychopharmacology</i> , 2011, 26, 183-192.	1.7	39
92	Neural correlates of emotional recognition memory in schizophrenia: Effects of valence and arousal. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 245-256.	1.8	27
93	Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. <i>Clinical Therapeutics</i> , 2011, 33, 1853-1867.	2.5	14
94	Relationship Between Insight into Cognition, Extrapyrarnidal Symptoms and Mental Illness in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 596-597.	2.3	10
95	Inflammatory alterations in dual diagnosis patients with schizophrenia and substance use disorders. <i>FASEB Journal</i> , 2011, 25, .	0.5	0
96	Endocannabinoids and Schizophrenia. <i>Pharmaceuticals</i> , 2010, 3, 3101-3126.	3.8	27
97	Sexual dimorphism of spatial working memory profiles in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2010, 15, 397-405.	1.3	10
98	Sex differences in memory processing in schizophrenia: An event-related potential (ERP) study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1-10.	4.8	23
99	Psychotic Symptoms as a Continuum between Normality and Pathology. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 140-151.	1.9	69
100	Pain perception in schizophrenia: No changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. <i>Journal of Psychiatric Research</i> , 2008, 42, 1010-1016.	3.1	67
101	Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2008, 100, 242-251.	2.0	128
102	Intrusion errors in explicit memory: Their differential relationship with clinical and social outcome in chronic schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2007, 12, 112-127.	1.3	14
103	Meta-Analysis of Depressive Symptoms in Dual-Diagnosis Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 792-799.	2.3	39
104	Sex Differences in the Cerebral Function Associated with Processing Of Aversive Stimuli by Schizophrenia Patients. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 136-141.	2.3	26
105	Fatal agranulocytosis: The use of olanzapine in a patient with schizophrenia and myelodysplasia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 297-300.	4.8	12
106	Effectiveness of antipsychotics: is the CATIE trial a tsunami?. <i>Canadian Family Physician</i> , 2007, 53, 97-8.	0.4	3
107	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 472-482.	27.0	249
108	Neural Correlates of Sad Feelings in Schizophrenia with and without Blunted Affect. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 909-917.	1.9	28

#	ARTICLE	IF	CITATIONS
109	Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: An fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 1-15.	1.8	68
110	Glycine and D-serine improve the negative symptoms of schizophrenia. <i>Evidence-Based Mental Health</i> , 2005, 8, 82-82.	4.5	7
111	CANTAB explicit memory is less impaired in addicted schizophrenia patients. <i>Brain and Cognition</i> , 2005, 59, 38-42.	1.8	63
112	Cognitive discernible factors between schizophrenia and schizoaffective disorder. <i>Brain and Cognition</i> , 2005, 59, 292-295.	1.8	54
113	Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 21-26.	4.8	46
114	On the trail of a cognitive enhancer for the treatment of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 219-232.	4.8	74
115	Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. <i>Schizophrenia Research</i> , 2005, 80, 131-133.	2.0	31
116	Switching atypical antipsychotics: a review. <i>Acta Neuropsychiatrica</i> , 2004, 16, 301-313.	2.1	12
117	Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic. <i>Brain and Cognition</i> , 2004, 55, 463-465.	1.8	8
118	Long-term effect of prefrontal lobotomy on verbal fluency in patients with schizophrenia. <i>Brain and Cognition</i> , 2004, 55, 466-469.	1.8	3
119	Procedural Learning in Schizophrenia Can Reflect the Pharmacologic Properties of the Antipsychotic Treatments. <i>Cognitive and Behavioral Neurology</i> , 2004, 17, 32-40.	0.9	30
120	Differential Effects of D2- and D4-Blocking Neuroleptics on the Procedural Learning of Schizophrenic Patients. <i>Canadian Journal of Psychiatry</i> , 1996, 41, S21-S24.	1.9	27
121	La conscience des déficits neurocognitifs dans la schizophrénie: une méta-analyse. <i>Sante Mentale Au Quebec</i> , 0, 39, 183-200.	0.1	15
122	Les RaeRae et Mahu: troisième sexe polynésien. <i>Sante Mentale Au Quebec</i> , 0, 40, 193-208.	0.1	12
123	Présentation. Histoire de la psychiatrie à l'Université de Montréal: passages et impasses. <i>Sante Mentale Au Quebec</i> , 0, 40, 11-33.	0.1	1